stockrowSplash Beverage Group, Inc.
EDVA Healthcare Biotechnology
Splash Beverage Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $73,100.00, down 98.2% from fiscal 2024.
- Revenue
- −99.6%
- EPS
- +95.6%
- Free cash flow
- −95.7%
- Total debt
- −100.0%
Quarter to June 2026, against a year earlier
Follow EDVA
Alert me
Splash Beverage Group, Inc. (EDVA) Altman Z-score
Splash Beverage Group, Inc.'s Altman Z-score for fiscal 2025 is −331.47, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −331.47 | (234.71) |
| FY2024 | −96.76 | (74.31) |
| FY2023 | −22.45 | (13.42) |
| FY2022 | −9.03 | 1.05 |
| FY2021 | −10.08 | 3.65 |
| FY2020 | −13.72 | 97.94 |
| FY2019 | −111.66 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (16.18) | — | −19.42 | |
| Retained earnings / total assets | (188.36) | — | −263.70 | |
| EBIT / total assets | (14.69) | — | −48.48 | |
| Market value of equity / total liabilities | 0.09 | — | 0.06 | |
| Sales / total assets | 0.08 | — | 0.08 | |
| Altman Z-score | Distress zone | −331.47 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −819.92 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| PPBT Purple Biotech Ltd. Sponsored ADR compare | 5.5× |
| SILO Silo Pharma, Inc. compare | −3.1× |
| BRTX Biorestorative Therapies, Inc. compare | −69.3× |
| EDVA Splash Beverage Group, Inc. | −331× |
| GNPX GENPREX compare | — |
| PPCB Propanc Biopharma Inc compare | — |
| REVB Revelation Biosciences, Inc. compare | — |
| ENLV Enlivex Ltd. compare | — |
| SLXN Silexion Therapeutics Corp compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets